New drug shows promise in taming rare inflammatory disease
NCT ID NCT04157348
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 32 times
Summary
This study tests if a new drug, benralizumab, works better than an existing one, mepolizumab, for people with a rare disease called EGPA that causes inflammation in blood vessels. About 140 adults with active EGPA will receive either drug for 52 weeks, and researchers will check if they achieve remission (no symptoms and low steroid use). The goal is to find a more effective treatment to control the disease and reduce reliance on steroids.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GRANULOMATOUS VASCULITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Denver, Colorado, 80206, United States
-
Research Site
Ann Arbor, Michigan, 48109, United States
-
Research Site
Rochester, Minnesota, 55905-0001, United States
-
Research Site
Albuquerque, New Mexico, 87106, United States
-
Research Site
Great Neck, New York, 11021, United States
-
Research Site
New York, New York, 10021, United States
-
Research Site
Philadelphia, Pennsylvania, 19104, United States
-
Research Site
Denison, Texas, 75020, United States
-
Research Site
Seattle, Washington, 98115, United States
-
Research Site
Brussels, 1070, Belgium
-
Research Site
Brussels, 1090, Belgium
-
Research Site
Calgary, Alberta, T2N 4Z6, Canada
-
Research Site
Hamilton, Ontario, L8N 4A6, Canada
-
Research Site
Toronto, Ontario, M5G 1E2, Canada
-
Research Site
Toronto, Ontario, M5T 3A9, Canada
-
Research Site
Dijon, 21079, France
-
Research Site
Marseille, 13915, France
-
Research Site
Montpellier, 34090, France
-
Research Site
Nantes, 44093, France
-
Research Site
Paris, 75014, France
-
Research Site
Paris, 75877, France
-
Research Site
Suresnes, 92151, France
-
Research Site
Toulouse, 31059, France
-
Research Site
Bamberg, 96049, Germany
-
Research Site
Freiburg im Breisgau, 79106, Germany
-
Research Site
Hamburg, 20251, Germany
-
Research Site
Kirchheim, 73230, Germany
-
Research Site
Lübeck, 23538, Germany
-
Research Site
Ashkelon, 7830604, Israel
-
Research Site
Beersheba, 84101, Israel
-
Research Site
Jerusalem, 91120, Israel
-
Research Site
Ramat Gan, 52621, Israel
-
Research Site
Rehovot, 7661041, Israel
-
Research Site
Tel Aviv, 6423906, Israel
-
Research Site
Cuneo, 12100, Italy
-
Research Site
Florence, 50141, Italy
-
Research Site
Milan, 20132, Italy
-
Research Site
Milan, 20162, Italy
-
Research Site
Naples, 80131, Italy
-
Research Site
Roma, 00168, Italy
-
Research Site
Torino, 10128, Italy
-
Research Site
Chiba, 260-0877, Japan
-
Research Site
Kita-gun, 761-0793, Japan
-
Research Site
Sagamihara-shi, 228-0815, Japan
-
Research Site
Sendai, 980-8574, Japan
-
Research Site
Shinjuku-ku, 162-8666, Japan
-
Research Site
Cambridge, CB2 0QQ, United Kingdom
-
Research Site
Leicester, LE3 9QP, United Kingdom
-
Research Site
London, SE19RT, United Kingdom
-
Research Site
Portsmouth, PO6 3LY, United Kingdom
Conditions
Explore the condition pages connected to this study.